The turnover rose 23.69 per cent to Rs 38,812 crore during the reporting year as against a turnover of Rs 31,377 crore, the report stated. Additionally, the report highlighted that the group is ...
Nevertheless, not all patients achieve a reduction of the levels of bone turnover markers, notably urinary N-telopeptide, and renal toxicity associated with bisphosphonates can limit their use.